Back to Authors

Satoskar, Abhay R.

0000-0001-5989-1520

Mayo Clinic

The Ohio State University Wexner Medical Center

Citations 1

MiR-16 regulates crosstalk in NF-κB tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages
Ghose, Jayeeta , Martella, Marianna , Viola, Domenico, Rocci, Alberto, Troadec, Estelle, Terrazas, César , Satoskar, Abhay R. , Gunes, Emine Gulsen , Donà, Ada , Sanchez, James F. , Bergsagel, P. Leif , Chesi, Marta , Rosen, Steven T. , Marcucci, Guido , Keats, Jonathan J. , Krishnan, Amrita , Caserta, Enrico , Bergsagel, P. Leif , Keats, Jonathan J , Khalife, Jihane , Pozhitkov, Alexander E. , Hofmeister, Craig C. , Pichiorri, Flavia

JCI Insight | October 8, 2019 | Volume: 4 | Issue: 21 | Pages: No page available

10.1172/jci.insight.129348 Get It

High levels of circulating miR-16 in the serum of multiple myeloma (MM) patients are independently associated with longer survival. Although the tumor suppressor function of intracellular miR-16 in MM plasma cells (PCs) has been elucidated, its extracellular role in maintaining a nonsupportive cancer microenvironment has not been fully explored. Here, we show that miR-16 is abundantly released by MM cells through extracellular vesicles (EVs) and that differences in its intracellular expression as associated with chromosome 13 deletion (Del13) are correlated to extracellular miR-16 levels. We also demonstrate that EVs isolated from MM patients and from the conditioned media of MM-PCs carrying Del13 more strongly differentiate circulating monocytes to M2-tumor supportive macrophages (TAMs), compared with MM-PCs without this chromosomal aberration. Mechanistically, our data show that miR-16 directly targets the IKKα/β complex of the NF-κB canonical pathway, which is critical not only in supporting MM cell growth, but also in polarizing macrophages toward an M2 phenotype. By using a miR–15a-16-1–KO mouse model, we found that loss of the miR-16 cluster supports polarization to M2 macrophages. Finally, we demonstrate the therapeutic benefit of miR-16 overexpression in potentiating the anti-MM activity by a proteasome inhibitor in the presence of MM-resident bone marrow TAM.